Details of the Drug

General Information of Drug (ID: DM6ZOUV)

Drug Name
Clazakizumab
Synonyms Clazakizumab; ALD518; CHEMBL2108589; BMS-945429
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
Crohn disease DD70 Phase 2 [2]
Rheumatoid arthritis FA20 Phase 2 [3]
Therapeutic Class
Antiviral Agents
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
4S38Z8RA9O
DrugBank ID
DB12849
TTD ID
D03UEO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN interleukin 6 (IL6) TTJH4Y5 IL6_HUMAN Inhibitor [4]
Interleukin-6 (IL6) TTT1V78 IL6_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04348500) Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02015520) Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452.